Rationale and design of the DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes)
- 7 August 2017
- journal article
- research article
- Published by Elsevier BV in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 27 (12), 1089-1097
- https://doi.org/10.1016/j.numecd.2017.08.001
Abstract
No abstract availableThis publication has 31 references indexed in Scilit:
- Reality and TruthCirculation, 2017
- Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice.Cardiovascular Diabetology, 2016
- Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4·4 million participantsThe Lancet, 2016
- Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care, 2014
- Update on developments with SGLT2 inhibitors in the management of type 2 diabetesDrug Design, Development and Therapy, 2014
- Dapagliflozin compared with other oral anti‐diabetes treatments when added to metformin monotherapy: a systematic review and network meta‐analysisDiabetes, Obesity and Metabolism, 2013
- The Cardiovascular Safety of Diabetes Drugs — Insights from the Rosiglitazone ExperienceNew England Journal of Medicine, 2013
- ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASDEuropean Heart Journal, 2013
- Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 DiabetesEndocrine Reviews, 2011
- Observational studies: going beyond the boundaries of randomized controlled trialsDiabetes Research and Clinical Practice, 2010